Results from the NIAGARA Phase III trial
AztraZeneca released the results of the NIAGARA phase III trial, where INFINZI (durvalumab) showed EFS and OS for MIBC.
Thomas Powles, Director of Barts Cancer Centre, one of the investigators, shared his thoughts:
“Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS and OS benefit versus chemo/cystectomy alone in muscle-invasive bladder cancer.”
Here are some comments from oncologists on this announcement on X:
“Perioperative durvalumab with EFS and OS benefit in MIBC. Great news for our patients and look forward to seeing the data.”
“Great news for muscle-invasive bladder cancer patients! Durvalumab demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial.”
“Addition of durvalumab to NAC before Cystectomy and continuation after Cystectomy (adjuvant) with increased EFS and increased OS.”
“Looking forward to data particularly in CR or ctDNA negative patients.. what’s the benefit of additional adjuvant durvalumab.”
“Just in: Durvalumab extends EFS and OS. In muscle-invasive bladder cancer —major news with IO moving earlier stages in bladder cancer!”
“Evidence for the efficacy of neoadjuvant immunotherapy is increasing. The ideal place is not yet clear.”
“Neoadjuvant chemo/IO taking over across oncology fields. Contribution of neoadjuvant vs. adjuvant IO remains mostly unknown, though.”
Read the official announcement and further details on this study.